While ongoing clinical trials are comprehensive in evaluating the efficacy of CFTR potentiators and correctors for application on mutation specific patients, improvements in infection and inflammation therapies would be highly desirable for all individuals with CF. Here, CFTR is linked to cystic fibrosis.